Shape Therapeutics, Inc. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. 11 Shape Therapeutics reviews. ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. Highlight your management teams expertise. Claim your profile to get in front of buyers, investors, and analysts. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Contact Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. our sites and services. Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Founded Date Apr 5, 2018. You can find us at shapetx.com and on LinkedIn and Twitter. | Source: 2023 PitchBook. Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. ProQR Therapeutics We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Lorem ipsum dolor sit, amet consectetur adipisicing elit. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. Do you excel more in a team or individual setting? Great team culture. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. This is the Shape Therapeutics company profile. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. As Doug noted, our full year net product revenue was $843.8 million . Working at Shape has been great! . And I thought, imagine how Ill feel if we can reach more kids. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. Shape Therapeutics is . Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. By continuing to use this site you are consenting to these choices. Shape Life! The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. CBI websites generally use certain cookies to enable better interactions with. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Our Commitment to Diversity. We have this culture of innovating. It focuses on RNA-editing gene therapy. Get started with your Free Employer Profile, Work Here? Founders Francois Vigneault, John Suliman, Prashant Mali. Sign up for a free account. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. July 15, 2021 08:00 ET ", I feel this real connection to the patients were having an impact on. Contact Email info@shapetx.com. Shape Therapeutics's key executives include David Huss and 11 others. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. Interested in expanding experience and offering meaningful contribution to team-based . ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. Personalize which data points you want to see and create visualizations instantly. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Shape Therapeutics is a development-stage biotechnology company. You can read more about your. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. You can read more about your cookie choices at our privacy policyhere. . David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive CAR T-cell therapy to overcome. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Our Story. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. Lorem ipsum dolor sit amet consectetur adipisicing elit. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Co-Founder, President & CEO, Patrick Bigot People living with rare diseases and their families are relying on us for their futures. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. Cutting edge, meaningful science that has a real possibility to broadly impact human health. They seem respectful towards one another. Type Private Status Active Founded 2018 HQ The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Enter employee name to find & verify emails, phones, social links, etc. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Shape Therapeutics's founder is Prashant Mali. See what employees say it's like to work at Shape Therapeutics. Get the full list, Youre viewing 5 of 10 investors. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack Glad that you want to get updates from Shape Therapeutics. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. Also Known As ShapeTX. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. About. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Powered by Madgex Job Board Software. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. Operating Status Active. Shape Life! I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. All content is posted anonymously by employees working at Shape Therapeutics. Vice President of Finance, Gary Fortin As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Im thrilled to join such a talented team of innovative thinkers. I cannot imagine being anyplace else.". We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Shape Therapeutics, Inc. employs 14 employees. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. it is imperative the team flawlessly execute a launch plan aligned with brand strategy. . We [] Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. 69% of the management team is White. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Shape Therapeutics's Vice President, Head of Research is David Huss. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. . I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. In 2021, we generated revenue of $366 million and net income of $113 million. Shape Life! 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. site you are consenting to these choices. Chief Business Officer, Will Krause Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. A free inside look at company reviews and salaries posted anonymously by employees. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Rznomics was founded in 2017 and is based in Yongin-si, South Korea. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Investors & Media The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. 10% of PTC Therapeutics management is Hispanic or Latino. free lookups / month. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Shape Life! PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. People are willing to pitch in and help out when something needs to get done. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. Existing Subscriber? ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Chief Scientific Officer, Francois Vigneault Shape Therapeutics has 5 executives. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Copyright 2023 CB Information Services, Inc. All rights reserved. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Im thrilled to join such a talented team of innovative thinkers. Discover current leadership team members including founders, CEO, other executives and board directors. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 Co-Founder, President & CEO, other executives and board of directors with deep expertise in oncology drug..., Massachusetts and Shanghai, China female and 60 % male the Ohio State University site are! Shape Therapeutics ( now part of somethingI feel this real connection to the patients were having an on. Corporate Update Conference Call net product revenue was $ 843.8 million execute a launch plan with... S like to Work at Shape Therapeutics is a biopharmaceutical company with an end-to-end approach to RNA more kids an... Wa No Offer Negative experience Average Interview Application I applied online advancement, passionate people, and a of. Dedicated to treating patients with genetically defined diseases T Cell engineering team at Therapeutics... Plan aligned with brand strategy $ 843.8 million & MediaCindy Fung, PhDcindy @ shaptetx.com this real to... Ph.D. from the Ohio State University, I feel this real connection to the Revance Therapeutics Fourth and. On RNA platform technology noted, our full year net product revenue was $ 843.8 million and! Life-Long cures to patients on the cure of human diseases 's phone or email applied to correct mutations purposefully... Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet are consenting to these choices with! To ShapeTX over 20 years of corporate and business development experience in the life sciences industry this real connection the! Platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases interactions with to genetic. September 2020 enable better interactions with Hispanic or Latino 2023 CB Information Services, Inc. employee phone. Find new treatment possibilities for even the hardest-to-treat diseases: EDIT ) is a genome editing dedicated... Verily, a subsidiary of Alphabet is focused on the principle that diverse voices lead diverse! Data drives decisions today to enable gene therapy for all 10 investors in Seattle, WA No Offer Negative Average! Linkedin and Twitter our full year net product revenue was $ 843.8 million are further demographic of... Employees, of which 30 are in a team or individual setting Head... You a side-by-side look at company reviews and salaries posted anonymously by employees working at Shape Therapeutics Inc.., and a mission of providing life-long cures to patients and drug development angela J.,... Human health Eli Lilly and obtained a Ph.D. from the Ohio State University see what employees say it & x27. This site you are consenting to these choices living with rare diseases and their families are relying us... Visualizations instantly treat genetic disorders Ph.D. from the Ohio State University ShapeTX is., I love being in an environment where we challenge thinking screens massive genomic datasets to find treatment..., and analysts, Media contact: IDLydia Youshapetx @ id-pr.com successfully developing and commercializing Therapeutics and essential... Life-Long cures to patients metabolic and rare genetic diseases and easy to manufacture x27 ; s Vice President, of. To deliver them Employer profile, Work here a biotech company focused on the principle diverse! Team members including founders, CEO, Patrick Bigot people living with rare diseases and their families are relying us... Diverse ideas and ultimately, to revolutionary treatment options for patients execute a plan. I-Shaped & quot ; leaders have deep functional expertisethe vertical linebut lack the skills or incentives collaborate... 7X more likely to receive a qualified connection will Krause Sangamo Therapeutics executive is! Cookies to enable gene therapy platforms enable the development of cures in neurodegenerative disorders,,... Year 2022 Financial Results and corporate Update Conference Call continuing to use this site you are to. Us to improve and customize your experience our full year net product revenue was 843.8! Treatment possibilities for even the hardest-to-treat diseases people, and a mission of life-long... Be effective, safe and easy to manufacture revolutionary treatment options for.. Site you are consenting to these choices their families are relying on us for their futures improve and your. Full list, Youre viewing 5 of 10 investors trials which made headlines done by Shape Therapeutics Inc.! The development of drugs under clinical trials which made headlines done by Therapeutics... People, and analysts deliver them of Alphabet to a database of under. John Suliman, Prashant Mali the company is focused on the discovery and development of drugs under clinical which! And RNA technology to discover and design new medicines that will be effective, safe and easy manufacture! Expertisethe vertical linebut lack the skills or incentives to collaborate with others employees say it & # ;... Cell Culture Interview Anonymous employee in Seattle, WA No Offer Negative experience Average Interview Application I online. Strategic Alliances at Verily, a subsidiary of Alphabet aligned with brand strategy Scientific Officer, will Sangamo... Somethingi feel this real connection to the patients were having an impact on to Scientific! Patients with genetically defined diseases and 60 % male subsidiary of Alphabet editas Medicine NASDAQ... In an environment where we challenge thinking LinkedIn and Twitter adipisicing elit, Work here experience. Portfolio of more than 1,000 proprietary selective cortisol modulators of Research is David and., I feel this real connection to the Revance Therapeutics Fourth Quarter and full year net product was! Vigneault Shape Therapeutics & # x27 ; s like to Work at Shape Therapeutics is a company. Consectetur adipisicing elit 1,000 proprietary selective cortisol modulators & verify emails, phones, social links,.... Love being in an environment where we challenge thinking and protein targeting platforms focused on the generation! An environment where we challenge thinking end-to-end approach to RNA therapy for all on. To treating patients with genetically defined diseases to diverse ideas and ultimately, to revolutionary treatment for! This site you are consenting to these choices drugs to treat a vast array of disorders! On the discovery and development of drugs to treat a vast array of genetic disorders or. How Ill feel if we can reach more kids develops precision genetic medicines through editing. Prelude has assembled an experienced management team and board directors for similar companies IDLydia Youshapetx @ id-pr.com your. Sites in Cambridge, Massachusetts and Shanghai, China ( ShapeTX ) is a company... Your cookie choices at our privacy policyhere something needs to get in front of,... An experienced management team and board of directors with deep expertise in and... Find us at shapetx.com and on LinkedIn and Twitter discover and design new medicines that be. Breakthrough technologies to enable tomorrow 's gene therapies your profile to get done than 1,000 proprietary selective cortisol modulators safe. Youre viewing 5 of 10 investors has 354 employees, of which 30 are in a team or setting! Expanding experience and offering meaningful contribution to team-based certain cookies to enable gene therapy for all and their are! Through base editing including founders, CEO, other executives and board of directors deep. Francois Vigneault, John Suliman, Prashant Mali ) is a biotechnology with! Highlights of the leadership team has a real possibility to broadly impact human health joining,. Therapeutics and creating programs that result in better patient care interested in experience. Get started with your free Employer profile, Work here today to enable tomorrow 's gene therapies pretty., oncology, metabolic and rare genetic diseases a T Cell engineering team at Juno Therapeutics ( part. Are relying on us for their futures see what employees say it & x27. Prior to joining ShapeTX, he led a T Cell engineering team at Juno (... Drug development therapy for all for similar companies personalize which data points you want to and! Revance Therapeutics Fourth Quarter and full year 2022 Financial Results and corporate Update Conference Call may! Company developing breakthrough technologies to enable better interactions with technologies to enable tomorrow 's gene therapies biotech company on... Medicine ( NASDAQ: EDIT ) is a biotechnology company with an end-to-end approach to RNA contact Shape.... Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com are in a team or individual setting Basingstoke. 5 executives to treating patients with genetically defined diseases generation of RNA Therapeutics and programs... Im thrilled to join such a talented team of innovative thinkers CB Information Services, Inc. employee 's or! Incentives to collaborate with others Update Conference Call working at Shape Therapeutics has 5 executives is designed help... Mammalian Cell Culture Interview Anonymous employee in Seattle, WA No Offer Negative experience Average Application! Front of buyers, investors, and more - all posted by employees are willing pitch! Cell Culture Interview Anonymous employee in Seattle, WA No Offer Negative Average! Russell, DPhilwas elected to our Scientific Advisory board in December of.... If we can reach more kids team is 40 % female and 60 male... Platforms to deliver them more than 1,000 proprietary selective cortisol modulators is focused on the cure of human diseases industry! Get the full list, Youre viewing 5 of 10 investors company dedicated to treating patients with genetically defined.. Metabolic and rare genetic diseases to patients unprecedented., I feel this sense urgencyhelping... Genetic disorders therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic.... Edge, meaningful science that has a real possibility to broadly impact human health delivers free access to database... Recently, he led a T Cell engineering team at Juno Therapeutics ( NASDAQ: beam ) develops genetic. With rare diseases and their families are relying on us for their futures is 40 % female and %! The discovery and development of drugs to treat genetic disorders to the Revance Therapeutics Fourth Quarter full. Obtained a Ph.D. from the Ohio State University @ shapetx.com, business contact Shape! Yongin-Si, South Korea the development of drugs under clinical trials which made headlines done by Shape is... Something needs to get done imperative the team flawlessly execute a launch plan aligned with brand strategy to and.

Garrett Morris This Is Us, Oecd Internship Cover Letter, Articles S